Financial Survey: CAMP4 Therapeutics (NASDAQ:CAMP) and Bolt Biotherapeutics (NASDAQ:BOLT)

Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) and CAMP4 Therapeutics (NASDAQ:CAMP – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Valuation and Earnings

This table compares Bolt Biotherapeutics and CAMP4 Therapeutics”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bolt Biotherapeutics $7.70 million 1.66 -$33.38 million ($14.97) -0.33
CAMP4 Therapeutics $5.32 million 44.71 -$80.40 million ($2.14) -1.77

Bolt Biotherapeutics has higher revenue and earnings than CAMP4 Therapeutics. CAMP4 Therapeutics is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Bolt Biotherapeutics and CAMP4 Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bolt Biotherapeutics 1 0 2 0 2.33
CAMP4 Therapeutics 1 1 8 1 2.82

Bolt Biotherapeutics currently has a consensus price target of $14.50, suggesting a potential upside of 195.32%. CAMP4 Therapeutics has a consensus price target of $10.44, suggesting a potential upside of 175.58%. Given Bolt Biotherapeutics’ higher possible upside, research analysts clearly believe Bolt Biotherapeutics is more favorable than CAMP4 Therapeutics.

Institutional and Insider Ownership

86.7% of Bolt Biotherapeutics shares are owned by institutional investors. 9.4% of Bolt Biotherapeutics shares are owned by company insiders. Comparatively, 21.7% of CAMP4 Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Bolt Biotherapeutics and CAMP4 Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Bolt Biotherapeutics -611.47% -154.11% -57.59%
CAMP4 Therapeutics -2,276.33% -182.39% -74.87%

Risk & Volatility

Bolt Biotherapeutics has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500. Comparatively, CAMP4 Therapeutics has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500.

Summary

Bolt Biotherapeutics beats CAMP4 Therapeutics on 9 of the 15 factors compared between the two stocks.

About Bolt Biotherapeutics

(Get Free Report)

Bolt Biotherapeutics is a clinical-stage biotechnology company based in Redwood City, California. It develops immunotherapies designed to direct the body’s immune system against cancer. The company’s Boltbody platform is designed to pair tumor-targeting antibodies with immune-stimulating components. Its pipeline has included BDC-3042, an investigational antibody intended to activate macrophages, immune cells that can help recognize and attack tumors. Bolt has also developed BDC-1001, an investigational HER2-targeting immune-stimulating antibody conjugate.

About CAMP4 Therapeutics

(Get Free Report)

CAMP4 Therapeutics is a clinical-stage biotechnology company developing RNA-based medicines for genetic diseases in which the body produces too little of an essential protein. The company’s research focuses on increasing the expression of selected genes to address these protein deficiencies. Its Regulatory Action on RNA (RAP) platform is designed to identify regulatory RNAs that influence gene expression. CAMP4 uses antisense oligonucleotides to target these RNAs, with the goal of adjusting the activity of disease-related genes.

Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.